Colon cancer cells frequently carry mutations that activate the β-catenin and mitogen-activated protein kinase (MAPK) signaling cascades. Yet how oncogenic alterations interact to control cellular hierarchies during tumor initiation and progression is largely unknown. We found that oncogenic BRAF modulates gene expression associated with cell differentiation in colon cancer cells. We therefore engineered a mouse with an inducible oncogenic BRAF transgene, and analyzed BRAF effects on cellular hierarchies in the intestinal epithelium in vivo and in primary organotypic culture. We demonstrate that transgenic expression of oncogenic BRAF in the mouse strongly activated MAPK signal transduction, resulted in the rapid development of generalized serrated dysplasia, but unexpectedly also induced depletion of the intestinal stem cell (ISC) pool. Histological and gene expression analyses indicate that ISCs collectively converted to short-lived progenitor cells after BRAF activation. As Wnt/β-catenin signals encourage ISC identity, we asked whether β-catenin activity could counteract oncogenic BRAF. Indeed, we found that intestinal organoids could be partially protected from deleterious oncogenic BRAF effects by Wnt3a or by small-molecule inhibition of GSK3β. Similarly, transgenic expression of stabilized β-catenin in addition to oncogenic BRAF partially prevented loss of stem cells in the mouse intestine. We also used BRAF V637E knock-in mice to follow changes in the stem cell pool during serrated tumor progression and found ISC marker expression reduced in serrated hyperplasia forming after BRAF activation, but intensified in progressive dysplastic foci characterized by additional mutations that activate the Wnt/β-catenin pathway. Our study suggests that oncogenic alterations activating the MAPK and Wnt/β-catenin pathways must be consecutively and coordinately selected to assure stem cell maintenance during colon cancer initiation and progression. Notably, loss of stem cell identity upon induction of BRAF/MAPK activity may represent a novel fail-safe mechanism protecting intestinal tissue from oncogene activation.
INTRODUCTION
The colon is lined by a single-layered epithelium folded into functional domains termed crypts, while the small intestine in addition contains villi that protrude into the intestinal lumen. The resulting tissue structure is highly ordered and contains a basal compartment with intestinal stem cells (ISCs) giving rise to transiently amplifying (TA) progenitor cells. These in turn differentiate into enterocytes and secretory cell types. 1 Cellular hierarchies are gradually modified during intestinal tumor initiation and progression by mutations in signaling pathways controlling homeostasis. Consequently, colon cancers can therefore exhibit gene activity characteristic for different intestinal cell types and colon cancer subtypes defined by such expression patterns differ in their therapeutic response. 2 It is largely unknown which oncogenic mutations modulate differentiation patterns during colon cancer progression and which constraints exist in the tumor to balance stem cell traits, proliferation and differentiation.
Colon cancer can form via different pathways, with conventional adenomas representing the most frequent benign precursor lesions. These initiate mainly, if not exclusively, via mutations activating the Wnt/APC/β-catenin signaling pathway in humans 3 and in the mouse. 4, 5 In the normal intestine, Wnt signals are emitted in the crypt base by secretory Paneth cells and myofibroblasts and received by ISCs and in an autocrine manner by Paneth cells. 1 Wnt signals inactivate the kinase GSK3β, resulting in stabilization of β-catenin and transcription of β-catenin/TCF4 target genes. 6 Wnt/β-catenin signals in the crypt are required for ISC maintenance. In line, loss of intestinal Wnt/β-catenin signals by genetic ablation of the transcription factor TCF4 results in loss of the stem cell compartment and ultimately in loss of the intestinal epithelium in the mouse. 7, 8 In contrast, activation of β-catenin is sufficient to modulate intestinal cellular hierarchies toward adenomatous stem cell fates. 9 Sessile serrated adenomas (SSAs) constitute a distinct class of premalignant tumors in the intestine, which are characterized by a saw-toothed and tufted tissue morphology, as well as by unique transcriptional, mutational and epigenetic patterns. [10] [11] [12] The most prevalent mutation in human SSA is BRAF V600E , representing an oncogenic alteration in the mitogen-activated protein kinase (MAPK) cascade, which is composed of consecutively activated rapidly accelerated fibrosarcoma (RAF), mitogen/extracellular 1 signal-regulated kinase (MEK) and extracellular signal-regulated kinase (ERK) kinases. In the normal intestine, MAPK activity mainly relays pro-proliferative cues in the progenitor compartment of the upper crypt. 13 BRAF-activated serrated human tumors show unique patterns of DNA methylation in CpG-rich regions 10, 14, 15 and strong nuclear β-catenin staining, indicative of tumorassociated activation of the Wnt/β-catenin pathway. 16, 17 Mice with an oncogenic BRAF V637E knock-in mutation develop generalized serrated hyperplasia, thus corroborating an initiating role for oncogenic BRAF in serrated adenoma. 18 Aging BRAF V637E knock-in mice exhibit focal tumor progression to dysplastic serrated adenoma and metastatic carcinoma. Similar to the findings in humans, more advanced stages of murine serrated tumors showed intensified MAPK signaling and activating mutations in the Wnt/β-catenin pathway. The specific epigenetic and mutational patterns of serrated tumors of mice and humans suggest that distinct evolutionary constraints exist in the progression of intestinal tumors that are initiated by activating BRAF mutations.
Here, we analyze a novel mouse model carrying an inducible transgene coding for human oncogenic BRAF. By analysis of intestinal tissue in vivo and in primary organotypic culture, we define effects of the main oncogenic driver pathways, MAPK and of Wnt/β-catenin, on the intestinal cellular hierarchies. We could show for the first time that high levels of MAPK activity can result in the loss of the affected tissue because such signals are not compatible with the maintenance of ISC identity. We further demonstrate that ISC loss induced by MAPK can be counteracted by β-catenin activity, providing a rationale for the concomitant activation of the BRAF/MAPK and β-catenin pathways during serrated tumor progression.
RESULTS

Oncogenic BRAF activates MAPK signal transduction and modulates cell fate-associated gene expression in colon cancer cells
We tested the effects of the two colon cancer-associated mutations BRAF V600E and BRAF V600K 19 in Caco2-tet colon cancer cells. To this end, we activated an inducible green fluorescent protein (GFP)-BRAF V600E or GFP-BRAF V600K in Caco2-tet cell by addition of doxycycline to the medium. We found that induction of either BRAF mutant induced the phosphorylation of the MAPK signal transducers MEK1/2 and ERK1/2, and activated transcription mediated by binding sites for the MAPK-associated transcription factor ELK to a similar extent (Figures 1a and b ). Both mutations have previously been characterized as highly activating. 20 Transcription mediated by FOXO3 or LEF/TCF, which are associated with PI3K/AKT and Wnt/β-catenin signal transduction, respectively, 7,21 was not altered by either mutation.
We assessed expression of MAPK target genes by quantitative reverse transcriptase PCR (qRT-PCR) and found that both BRAF V600E and BRAF V600K activated Phlda1 and Dusp6, whereas Spry2 was not BRAF-responsive in Caco2-tet cells (Figure 1c ). Next, we determined whether oncogenic BRAF modulates expression of Birc5 and Axin2, which are highly active in stem cell-like colon cancers, as well as Muc2 and Krt20, which are active in Goblet celllike colon cancers. 2 We found that Birc5 and Axin2 were gradually inhibited by increasing amounts of BRAF V600E or BRAF V600K , whereas Muc2 and Krt20 were progressively activated ( Figures  1d and e ). These results suggest that activation of the BRAF/MAPK signaling axis can affect cell fate-associated transcriptional activity in colon cancer cells and thus may modulate cell differentiation choices during intestinal tumor initiation and progression.
Transgenic expression of oncogenic BRAF induces intestinal serration
To study the effects of oncogenic BRAF on cell hierarchies in the intestinal epithelium, we engineered an inducible transgene for the human oncogene BRAF V600K linked to the fluorescent protein tdTomato into a modified Gt(ROSA26)Sor locus 22 of murine embryonic stem cells and derived transgenic mice by diploid aggregation (Figure 2a ). In transgenic mice, BRAF V600K expression in the intestine was induced by administration of doxycycline via the drinking water. We were able to induce BRAF V600K in transgenic mice for up to 4 days before they showed signs of distress and had to be killed.
In the non-induced state, the small intestine of transgenic mice displayed regular architecture and a smooth epithelial surface with cylindrical enterocytes admixed with Goblet cells. Paneth cells, as identified by eosinophilic cytoplasmic granules, were restricted to the bases of the crypts. Significant morphologic alterations were found after 3 and 4 days of BRAF V600K induction (Figure 2b, Supplementary Figure 1 ). The villus surface became saw-toothed, and tufts of aggregated enterocytes were seen at the villus tip. Basal positioning of nuclei in the epithelium was lost, nuclei were enlarged and the nucleus to cytoplasm ratio was increased. The contact surface of the cells to the basal membrane often appeared to be narrowed, resulting in a hobnail appearance of the cells and the presence of discohesive cell clusters. Paneth cells lost their strict location at the base of the crypt and were also found at more luminal positions. We frequently observed the formation of rounded glands at crypt-to-villus junctions, which contained Paneth cells. We also found that maturation of secretory lineages was perturbed, and we frequently observed intermediary cells that expressed both Goblet and Paneth cell markers (Supplementary Figure 2 ).
In the large intestine changes were similar, yet less pronounced (Figure 2b, Supplementary Figure 3 ). We observed generalized Goblet cell-rich epithelial serration with widened luminal openings of crypts. Similar to the surface alterations in the small bowel, tufts of clustered cells projected into the lumen. Associated with the widening of crypts and luminal openings, the submucosal space between the epithelium and the muscularis appeared reduced to only few visible fibroblasts.
Transgenic expression of oncogenic BRAF induces MAPK hyperactivation in the intestinal epithelium
We analyzed transgene expression and resulting changes in MAPK cascade activity in the intestinal epithelium by western blots and immunohistochemistry (IHC) (Figure 2c , Supplementary Figures 4  and 5 ). We detected low levels of endogenous RAF proteins in the intestinal epithelium of non-induced mice, while transgenic BRAF V600K contributed to a more pronounced RAF signal in induced mice. In line, only low levels of the phosphorylated active forms of MEK and ERK were present in non-induced mice, but phosphorylation was stronger in induced animals. We compared phospho-MEK1/2 and phospho-ERK1/2 levels in the intestinal epithelium of induced mice with levels found in the human colon cancer cell lines RKO and HT29, which both harbor a BRAF V600E mutation. MEK1/2 and ERK1/2 showed activity levels of various strengths in the intestinal epithelia of mice and in cell lines. Phosphorylated ERK1/2 was most strongly elevated in RKO cells. These western blot analyses demonstrate that transgenic BRAF V600K induces MAPK activity in the intestine of mice to levels comparable, but not exceeding those found in human colon cancer cell lines.
Phospho-Mek1/2 and phospho-ERK1/2 signals were generalized in all compartments spanning crypt bases to villus as assessed by IHC ( Supplementary Figures 4 and 5 ). However, the proliferative zones were only slightly expanded after BRAF V600K induction in both small and large intestine (Supplementary Figure 6 ). We used qRT-PCR to quantify expression of well-known MAPK target genes in the intestine and found strong induction (Figure 2d ), comparable to that seen in foci of dysplastic progression in mice harboring a knock-in allele of oncogenic BRAF V637E . 18 MAPK target genes were activated in both crypts and villi of BRAF V600K -induced mice (Supplementary Figure 7 ).
Transgenic expression of oncogenic BRAF causes loss of ISCs
We next analyzed the effects of amplified MAPK signal transduction on the intestinal crypt, which contains ISCs and is essential for tissue maintenance. In control mice, ISCs and secretory Paneth cells were both restricted to the crypt base, as assessed by RNA in situ hybridization for Olfm4 23 and Lysozyme IHC, respectively (Figure 3a and Supplementary Figure 4 ). Olfm4-positive ISCs had characteristic wedge-like shapes and were mostly proliferative, as shown by Ki67 staining. In striking contrast to non-induced controls, crypts of BRAF V600Kinduced mice displayed only very weak Olfm4 signals already 3 days after induction, suggesting an exhaustive loss of ISCs. Ki67-positive proliferative cells were frequently found at the crypt base. However, these did not have the characteristic shape of ISCs, but were round to cylindrical, resembling proliferative cells of the TA zone. Furthermore, Lysozyme-positive Paneth cells were displaced from the crypt base and strongly positive in Periodic acid-Schiff (PAS) staining, resembling Goblet cells and confirming our previous analyses (see Supplementary Figure 2 above).
To ascertain the loss of ISCs in crypts upon transgenic BRAF V600K induction, we analyzed the expression of several ISC marker genes 23 by qRT-PCR and found all markers strongly reduced in the induced intestines ( Figure 3b ).
To quantify the fraction of ISCs in normal versus BRAF-induced crypts, we mated BRAF V600K transgenic and firefly luciferase/ tdTomato-transgenic control mice to Lgr5-EGFP stem cell-marking reporter mice. 24 Using fluorescence-activated cell sorting (FACS), we found that crypt cell suspensions isolated from control mice contained between 3 and 8% of enhanced GFP (EGFP)-positive stem cells, while crypt cell suspensions isolated from BRAF V600K transgenic mice induced for 3 days contained o 0.2% EGFPpositive ISCs (Figure 3c ).
Transgenic expression of oncogenic BRAF promotes TA cell generation combined with ISC depletion
In order to elucidate the fate of ISCs upon BRAF V600K induction, we first evaluated end points of apoptotic and senescence programs, which can be triggered as a response to BRAF. 25, 26 We found that induction of BRAF V600K induced significant DNA damage in the intestine, as demonstrated by immunofluorescence analysis of phosphorylated histone γH2A. However, we did not find increased apoptosis in BRAF V600K -induced intestinal tissues, as assessed by cleaved caspase 3 IHC ( Supplementary Figure 8) . Similarly, oncogene-induced senescence was not observed, as indicated by lack of staining for senescence-associated β-galactosidase ( Supplementary Figure 9 ). We next analyzed gene expression in BRAF V600K -induced ISCs, using tdTomato-BRAF V600K ;Lgr5-EGFP or control tdTomato-luc; Lgr5-EGFP compound transgenic mice. For this, we sorted cells displaying both red and green fluorescence, marking activity of the BRAF V600K or control transgenes and the Lgr5-EGFP stem cell-specific reporter, respectively. As almost no double-positive cells were detected 2 or 3 days after BRAF V600K induction (see Figure 3c and data not shown), we induced the BRAF V600K transgene for only 24 h, and could isolate sufficient numbers of (Figure 4a ). We also identified many novel BRAF target genes in the intestine, prominently among these the putative signal transducer gene Anxa10, which has recently been identified as a specific marker for SSA in human patients 27 (Figures 4b and c ).
We used gene set enrichment analysis 28 to analyze activities of gene expression programs in the sorted ISCs ( Figure 4d ). We evaluated gene signatures comprising MAPK or β-catenin target genes, as well as signature genes enriched in stem cells or proliferative committed TA cells of the intestinal epithelium. [29] [30] [31] [32] As expected, we found that a signature of MAPK target genes was strongly induced by BRAF V600K in ISCs when compared with luciferase-expressing control ISCs. However, signatures of β-catenin target genes were not significantly changed. Strikingly, we found a strongly activated signature of proliferative TA cells in the BRAF V600K -induced sorted Lgr5-EGFP-positive cells, while the ISC signature was not significantly altered at this early time point after transgene induction (Figure 4d and Supplementary Figure 10 ). Taken together, these findings show that ISC and TA cell gene expression programs are both active side by side in the BRAF V600K -expressing ISCs 24 h after induction, and the latter is strongly enhanced. Our gene expression data thus confirm and extend the morphological analyses, and suggest that ISCs rapidly and collectively convert to committed TA progenitors after BRAF V600K induction. Furthermore, secretory lineages are perturbed and intermediate secretory cells emerge (for a model of the resulting crypt cell types, see Figure 4e ).
Effects of oncogenic BRAF in organotypic culture can be rescued by MEK inhibition
To follow tissue development and signal transduction in the intestinal epithelium after BRAF V600K induction in more detail, we took advantage of organotypic primary tissue culture. 33 We were unable to establish organoids from intestines of mice induced for BRAF V600K expression for 3 or 4 days, further supporting our finding that ISCs are lost by the treatment. Organoids prepared from non-induced BRAF V600K transgenic mice that were maintained without doxycycline were organized into radial crypts and a central differentiated villus domain containing debris of extruded cells, as expected. Upon BRAF V600K induction, organoids underwent rapid changes: crypts became progressively wider and shallower, until they were indistinguishable from the central villus tissue (Figure 5a ). Time-lapse photography revealed rapid development of an irregular and highly motile apical epithelial surface and frequent loss of Paneth cell localization (data not shown). Sections of induced organoids frequently displayed serration, reminiscent of the morphological changes observed in vivo ( Supplementary Figure 11 ). These induced organoids showed a markedly reduced expression of crypt domain markers, such as for the stem cell markers Lgr5, Olfm4 and Cd44, the Paneth cell marker Mmp7, the Wnt target gene Axin2 and for the Goblet cell marker Muc2. In contrast, expression of the villus enterocyte marker Fabp2 was not significantly altered (Figure 5b ). Within 1-2 days of induction, organoids lost all structure and disintegrated. These data are in agreement with the in vivo analyses, and validate that following BRAF V600K induction epithelial serration is induced and ISCs are lost in a tissue-intrinsic manner. In addition, we also observed loss of the proliferative compartment, which probably can no longer be maintained in the absence of stem cells and after loss of crypt topology. The enhanced disintegration of the tissue architecture in vitro can likely be attributed to the lack of supporting effects from the surrounding tissues, which are an important source for growth factors in vivo but are lacking in organotypic culture. 34 In order to dissect signaling cascades downstream of oncogenic BRAF, we treated organotypic cultures with small-molecule inhibitors. In a series of proof-of-principle experiments, we first assessed the effects of PLX4720, 35 a specific inhibitor of BRAF V600E and possibly other oncogenic forms of BRAF. In non-induced organotypic cultures, PLX4720 did not cause any effects. When BRAF V600K was induced using a low concentration of doxycycline, PLX4720-treated cultures preserved crypt/villus topology and survived for several days, indicating inhibition of BRAF V600K by PLX4720 (Figures 5c and d) . Under these conditions, PLX4720 also suppressed the strong activation of the MAPK target genes Fos and Dusp6 that were induced by BRAF V600K (Supplementary Figure  12 ). To establish whether increased MAPK activity is causative for the loss of ISCs and crypts, we inhibited the downstream MEK1/2 kinases using AZD6244 36 and alternatively the phosphatidylinositol 3 kinase cascade using the specific inhibitor GDC0941. 37 Significantly, MEK inhibition by AZD6244 had a similar protective effect as PLX4720 and supported organoid survival in the presence of doxycycline (Figure 5d ). In contrast, inhibition of the phosphatidylinositol 3 kinase cascade by GDC0941 did not rescue organoid survival. These results indicate that oncogenic signals causing serration and loss of ISCs are transduced via activation of the MAPK cascade.
Activation of Wnt/β-catenin signaling rescues ISC loss after induction of oncogenic BRAF
In our mouse model, induction of transgenic BRAF V600K resulted in strong MAPK signal activation and in epithelial serration, yet also in loss of ISCs. As the ISC compartment is maintained by Wnt and Notch signals, 1 we tested the effects of the ligands Wnt3a and Jagged1, which are known to activate the Wnt and Notch pathways in organotypic culture. 33 We found that Wnt3a, but not Jagged1, led to a partial rescue of organoid integrity (Figure 6a ). Furthermore, we used the selective GSK3β-inhibitor CHIR99021, 38 which stabilizes β-catenin. 39 In organotypic culture, CHIR99021 was tolerated and resulted in a visible expansion of crypt domains after 2 days, probably due to the induction of ectopic β-catenin activity that is normally restricted to the crypt base (Figure 6b) . Remarkably, when we induced BRAF V600K in cultures, inhibition of GSK3β by CHIR99021 resulted in a substantial rescue of crypt-villus architecture and in organoid survival (Figures 6a and b ). We observed that even when BRAF V600K was strongly induced by high levels of doxycycline, GSK3β inhibition resulted in the survival of many organoids. Their crypt domains persisted while becoming enlarged and hyperplastic. In agreement with the changes in organoid architecture observed, we found that CHIR99021 strongly activated the ISC marker genes Lgr5 and Olfm4, and that this activation was strong even in the presence of induced BRAF V600K (Figure 6c) .
We have previously shown that transgenic expression of stabilized β-catenin promotes stem cell identity in intestinal epithelium. 9 We therefore asked whether activation of β-catenin signaling could rescue the stem cells loss caused by transgenic BRAF V600K in vivo. To this end, we engineered a triple transgene into an inducible Gt(ROSA26)Sor locus, consisting of tdTomato, BRAF V600K and stabilized β-catenin. We found that BRAF V600K / β-catenin stab compound transgenic mice also develop serration. Importantly, and in contrast to the BRAF V600K mice analyzed before, we observed the presence of many residual Olfm4-positive ISCs 3 days after transgene induction (Figure 6d ). Taken together, our experiments demonstrate that enhanced Wnt/β-catenin pathway activity can strongly reduce the loss of ISCs in vitro and in vivo, caused by BRAF V600K -induced MAPK hyperactivation.
Finally, we analyzed ISCs in a murine tumor progression model, based on knock-in of a BRAF V600E homolog 18 (Figure 6e and Supplementary Figure 13 ). These mice display serrated intestinal hyperplasia upon oncogenic activation of BRAF, and develop progressive dysplastic foci that frequently contain activating mutations in the Wnt/β-catenin pathway in addition to the initiating oncogenic BRAF. When visualizing ISCs by Olfm4 in situ hybridization, we found that BRAF-activated hyperplastic intestines showed diffuse and scattered signals in neighboring crypts, whereas intestines of control mice displayed a continuous band of Olfm4-positive crypts. We also observed a strong reduction of mature Paneth cells, as assessed by Lysozyme IHC. We next used qRT-PCR to assess expression levels of the ISC markers Lgr5 and Ascl2 during the different stages of tumor progression in BRAF V637E mice (Figure 6f ). We found that hyperplastic intestines showed a marked reduction of expression for both Lgr5 and Ascl2 relative to non-recombined control intestines. In contrast, progressive dysplastic foci that frequently contain Wnt/β-catenin mutations displayed an increase in ISC marker expression. These data support and extend our previous results, suggesting that an initiating BRAF mutation can reduce the ISC pool, whereas enhanced Wnt/β-catenin signals expand the ISC pool at later stages of serrated intestinal tumor progression.
DISCUSSION
We report a novel oncogene mouse model that is based on conditional activation of transgenic BRAF V600K . Induced mice showed generalized serration of the intestinal epithelium, combined with strong reduction of the ISC pool.
Transgenic induction of oncogenic BRAF rapidly induced a phenotype that displayed striking parallels to SSA in the human colon. In particular, the mouse model showed a serrated epithelial morphology, tufting of cells at the luminal borders, reduction of the interluminal mesenchymal tissue and widening of the colonic crypts, 40 which are all features of human SSA. We therefore conclude that activation of MAPK signaling by oncogenic BRAF is sufficient to induce multiple pathognomonic features of SSA. We furthermore noticed a high extent of cellular atypia (that is, a high nucleus-to-cytoplasmic ratio) normally associated with later stages of serrated tumor progression in humans.
Transgenic expression of BRAF V600K in the intestinal epithelium converted stem cells collectively into proliferative TA cells. The resulting ISC depletion was counteracted by upregulation of Wnt/β-catenin signaling by Wnt3a ligand or by small-molecule inhibition of GSK3β in organotypic culture, or by transgenic expression of stabilized β-catenin in the mouse intestine. Both high MAPK and β-catenin activity has been noted in human SSA 16, 17 and in BRAF-driven serrated intestinal tumors in the mouse. 18 Our data suggest that the concomitant activation of MAPK and β-catenin could be required to assure stem cell and consequently tumor tissue maintenance during progression of SSA, and our ISC marker analysis during serrated tumor progression in the mouse is in agreement with such a model. The transgenic mouse model presented here expresses BRAF V600K to an extent that exceeds endogenous BRAF transcript or protein levels in normal intestinal cells (for quantification of transgene expression, see Figure 2c and Supplementary  Figure 14 ). This is in contrast to previous mouse models of oncogenic activation of BRAF, which used knock-in alleles. 18, 26 As a consequence, BRAF V600K induction in our mouse model results in immediate and strong activation the MAPK cascade. Consequently, MAPK target genes in transgenic BRAF V600K mice were induced to levels characteristic of more advanced stages of tumor progression obtained in BRAF V637E knock-in mice. 18 Mechanisms of how MAPK signals are further intensified in serrated intestinal tumors of mice and humans after the initial BRAF mutation remain to be further defined. It is of note that amplification of oncogenic BRAF has been found in colon cancer cell lines that were resistant to MEK inhibition 41 and also in BRAF-mutant human colorectal cancer, 42 demonstrating that high levels of oncogenic BRAF are tolerated in more advanced tumor stages.
Oncogenic forms of KRAS and BRAF are mutually exclusive drivers of oncogenic progression in human colon cancer. Although both oncogenes activate the MAPK cascade, differences also exist: first, KRAS activates a number of further signal transducers in addition to BRAF, 43 and second, oncogenic KRAS, but not BRAF, is subject to strong additional feedback control within the MAPK cascade. 44 These differences may explain why BRAF-mutated tumors have distinct molecular features and therapeutic profiles compared with BRAF non-mutated tumors, including those that are KRAS mutated. 3 Similar to BRAF, oncogenic KRAS can also initiate serrated lesions in the mouse, 45 but in contrast to BRAF, tumor progression in KRAS-transgenic mice crucially depends on loss of the tumor-suppressor Ink4a/ARF, but not on Wnt/β-catenin activation. The KRAS and BRAF oncogenes may also have contrasting effects on cellular hierarchies in the intestine, as oncogenic KRAS in combination with loss of APC can induce ectopic stem cells in the mouse intestine, 46 and KRAS mutations produced cells that favor ISC over TA cell fate and thus spread within individual crypts. 47 In contrast, our results suggest that oncogenic activation of BRAF would support the adoption of TA over ISC cell fate, which would result in preferential exclusion from the stem cell pool and clonal elimination. However, this assumption has not been tested on a clonal basis here.
Wnt and MAPK signaling have been shown to co-operate during conventional intestinal tumor progression, with APC/β-catenin pathway mutations occurring first: nuclear localization of β-catenin and expression of cancer stem cell markers after loss of APC are increased by mutational activation of the MAPK-controlling GTPase KRAS, 48, 49 and in turn KRAS can be stabilized by β-catenin activity. 50 In contrast, activation of MAPK signaling downstream of oncogenic BRAF can inhibit β-catenin effects in melanoma. 51 Therefore, interactions between the two signaling cascades may be highly cell type-and context-specific. 52 To assess whether BRAF/MAPK activation may immediately alter transcription of β-catenin target genes during serrated tumor development, we analyzed FAC-sorted residual ISCs after shortterm induction of BRAF V600K by microarrays, but found no immediate changes in β-catenin target gene expression. A molecular mechanism connecting the BRAF-hyperactivated MAPK and the physiological β-catenin pathway in the intestine may therefore depend partly on competing downstream transcriptional programs promoting progenitor TA versus ISC cellular states, respectively.
Although the intestinal epithelium is highly proliferative and has a rapid turnover, intestinal tumor progression is a long-term process. This suggests the existence of strong protective mechanisms limiting survival of cells that acquired oncogenic mutations in order to prohibit tumor initiation or progression. Mutational activation of BRAF elicits oncogene-induced senescence and apoptosis in melanoma. 25, 53, 54 However, in agreement with another recent publication, 18 we observed neither senescence nor apoptosis-related cleaved caspase3 in the intestine after oncogenic BRAF induction, although it has been reported before under similar conditions. 26 Strikingly, our data suggest the existence of a novel alternative fail-safe mechanism that may block tumor development after mutational activation of BRAF, that is, by oncogene-induced loss of stem cells. This mechanism could represent the prototype of a more general paradigm, as oncogene activities could possibly result in cellular signaling states incompatible with the maintenance of stem cell identity in other tissues, too, leading to discontinuation of the mutated cell progeny and clonal elimination. Further studies of oncogeneinduced loss of stem cells could thus lead to new strategies to exploit colon cancer vulnerabilities.
MATERIALS AND METHODS Mice
Transgene cassettes were constructed by linking tdTomato to human BRAF V600K and/or murine stabilized mutant Ctnnb1 (S33A, S37A, T41A and S45A) and/or firefly luciferase via 2A peptides, and subsequent cloning of these gene combinations into a doxycycline-inducible expression cassette flanked by wild-type and mutant loxP sites. Transgenes were integrated into the previously modified Gt(ROSA)26Sor locus of F1 hybrid B6/129S6 embryonic stem cells by Cre recombinase-mediated cassette exchange. Recombined embryonic stem cell clones were identified by Southern blotting, as described previously. 22 Animals were generated by diploid aggregation. Previous experiments in adult mice have shown that this configuration results in high transgene induction in the intestinal epithelium, lower induction in some other tissues including skin and no discernible transgene expression in most tissues tested (data not shown). Mice were housed at a 12 h/12 h light/dark cycle and fed ad libitum. Firstand second-generation transgenic mice with apparent 100% transgenic contribution were used for experiments (at least n = 4 mice per genotype and time point). Transgenes were induced by administration of doxycycline (4 mg/ml) provided in a 1% sucrose solution via the drinking water. Primer sequences for genotyping are given in Supplementary  Table 1 . Termination criteria for the animal experiments were either weight loss or apparent distress, as indicated by a reduction of foraging activity or shivering. Animal experimentation was approved by Berlin authorities LAGeSo (G0185/09).
Organotypic culture
Organoid cultures were initiated and propagated as described in reference Sato et al., 33 in 24-well or 48-well plates, using 15 or 30 μl of Matrigel (BD, Heidelberg, Germany) per well. Crypt culture media were exchanged every other day, and cultures were passaged every 5-7 days. For all smallmolecule inhibitors, maximal tolerated concentrations were determined in organoid culture in the absence of transgenic induction. The following inducers and small-molecule inhibitors were used: doxycycline (250 ng/ml, 500 ng/ml and 2 μg/ml for weak, intermediary and strong transgene induction, respectively), PLX4720 (42 μM), AZD6244 (8 μM), GDC0941 (500 nM), CHIR99021 (6 μM). Jagged1 (AnaSpec, Seraing, Belgium) and Wnt3a (Cell Signaling, Danvers, MA, USA) peptides were used at 1 μM and 100 ng/ml, respectively. For signal inhibition experiments, doxycycline and small-molecule inhibitors were added at the same time, and wells were photographed 24, 36, 48 and 72 h after induction. Organoid survival was quantified from photographs, from at least three independent experiments.
Cell culture
Caco2-tet cells were tested to have no mutations in BRAF, KRAS, NRAS and MAP2K1 (own unpublished data). Cells were maintained in Dulbecco's modified Eagle's medium containing 10% fetal calf serum. Caco2-tet cells have previously been modified to express a second-generation tetracycline-regulated transactivator and transcriptional silencer. 44, 55 Caco2-tet were transfected using Lipofectamine 2000 (Life Technologies, Darmstadt, Germany) as per the manufacturer's instructions, using tetracyclineinducible plasmids coding for GFP, or combinations of GFP with BRAF V600E or BRAF V600K . We used luciferase reporter constructs with multimerized ELK, FOXO3 or LEF/TCF sites. Generally, 6 h after transfection, medium was exchanged to Dulbecco's modified Eagle's medium, 0.2% fetal calf serum and 2 μg/ml doxycycline for induction. Cells were harvested 24-36 h after transfection. Reporter activity was measured using a dual-luciferase-assay (Life Technologies). FACS sorting of Caco2 cells for GFP expression was done using an Aria II sorter (BD).
IHC, RNA in situ hybridization, western analysis
For IHC and in situ hybridization, tissues were fixed in 4% formaldehyde, dehydrated via a graded ethanol series, embedded in paraffin and sectioned at 4 μm. The following antibodies were used for IHC: anti-KI67 (1:200; #ab16667 Abcam, Cambridge, UK), anti-RFP (1:200; #600-401-379 Rockland, Gilbertsville, PA, USA), anti-Lysozyme (1:200; #18-0039 Life Technologies), anti-ITF (1:100; Santa Cruz, Dallas, TX, USA), anti-phospho-MEK1/2 (1:100; #9121 Cell Signaling), anti-phospho-ERK1/2 (1:200; #9101 Cell Signaling). ImmPRESS secondary antibody and NovaRED substrate kits (Vector Labs, Burlingame, CA, USA) were used for IHC. Olfm4 in situ hybridization was carried out using standard protocols. Primer sequences flanking the in situ probe are listed in Supplementary Table 1 . DNA damage was detected by staining for γH2AX, using the HCS DNA damage kit (Life Technologies), following the manufacturer's instructions. For SA-β-galactosidase staining, fresh tissues of induced and control mice were embedded in Tissue TEK (Sakura, Alphen, The Netherlands), snap-frozen and sectioned at 20 μM on a cryostat. Sections were stained using the Senescence β-Galactosidase Kit (Cell Signaling), following the manufacturer's instructions.
For western analysis, purified intestinal epithelium or cell lines were lysed in sodium dodecyl sulfate lysis buffer and protein content was quantified by a BCA assay (Thermo Fisher, Waltham, MA, USA). Twenty or 40 μg of protein lysates was separated on 12% polyacrylamide gels, and blotted onto nitrocellulose membranes. The following antibodies were used: anti-phospho-MEK1/2 (1:500; #9121 Cell Signaling), anti-phospho-ERK1/2 (1:500; #9101 Cell Signaling), anti-MEK1 (1:500; #9122 Cell Signaling), anti-ERK1/2 (1:500; #9102 Cell Signaling), RAF (1:200; #55522 Santa Cruz), anti-BRAF(V600E) (1:400; Spring Bioscience, Pleasanton, CA, USA), glyceraldehyde 3-phosphate dehydrogenase (1:10 000; #AM4300 Life Technologies). Alexa fluorophore-coupled secondary antibodies and an Odyssey scanner (Li-Cor, Bad Homburg, Germany) were used for visualization.
qRT-PCR and microarray analysis
For RNA analysis, villi were scraped from the inner intestinal surface after initial washing steps, whereas crypts were isolated by filtering (70 μm, BD) after phosphate-buffered saline/EDTA treatment, as described in Sato et al. 33 For total tissue analysis, small pieces of the intestine were homogenized in Trizol (Life Technologies) using a Tissue Lyser machine (Qiagen, Hilden, Germany). Single-cell suspensions for FACS were prepared by digesting crypts of compound transgenic mice in 500 μg/ml trypsin and 0.8 μ/ml DNAseI for approximately 20 min at room temperature. Cells were microscopically examined for proper dissociation, washed and resuspended in Suspension Minimal Essential Medium (SMEM) (Life Technologies) containing DNAseI and subsequently filtered (30 μM; Celltrics filter Partec, Münster, Germany). For FACS, an Aria SORP (BD) was used. For each profile, between 2000 and 20 000 cells were sorted directly into Qiagen buffer RLT containing 1% β-mercaptoethanol.
Total RNA was isolated from tissue and cell samples using RNeasy kits (Qiagen). Complementary DNA was synthesized from total RNA using the Transcriptor High Fidelity cDNA synthesis kit (Roche, Penzberg, Germany) as per the manufacturer's instructions. qRT-PCR was carried out using SYBR green (Promega, Mannheim, Germany) standard protocols. Relative expression was calculated using the ΔΔCt method and GAPDH (human) or Pmm2 (mouse) gene expression for normalization. qRT-PCR primer sequences are provided in Supplementary Table 1 . Lgr5 and Ascl2 gene expression in BRAF V637E mice was determined by Taqman qRT-PCR (Qiagen), as described in Rad et al. 18 Gene expression profiling from FACSsorted cell populations was done at AROS Applied Biotechnology (Aarhus, Denmark) using Illumina MouseRef-8 v2 chips and the NuGEN procedure for probe labeling. Expression data were calculated and normalized in Genome Studio GX 1.9 (Illumina, San Diego, CA, USA), using quantile normalization. Gene expression data were visualized using MultiExperiment Viewer (http://www.tm4.org). Gene set enrichment analysis was performed using pre-normalized Illumina gene expression data, following the authors guidelines. 28 Gene signatures and associated references are listed in Supplementary Table 2 . Gene expression data are available in GEO under GSE50678.
